Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

@article{Ettinger2017NonSmallCL,
  title={Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.},
  author={David S. Ettinger and Douglas Edwin Wood and Dara L. Aisner and Wallace L Akerley and Jessica M Bauman and Lucian R. Chirieac and Thomas A D'amico and Malcolm M Decamp and Thomas J. Dilling and Michael Christian Dobelbower and Robert C Doebele and Ramaswamy Govindan and Matthew A. Gubens and Mark W. Hennon and Leora A Horn and Ritsuko U. Komaki and Rudy P. Lackner and Michael Lanuti and Ticiana A. Leal and Leah J. Leisch and Rogerio A Lilenbaum and Jules Lin and Billy W. Loo and Renato Alas Martins and Gregory Alan Otterson and Karen L Reckamp and Gregory J Riely and Steven E. Schild and Theresa A. Shapiro and J. P. J. Stevenson and Scott James Swanson and Kurt T Tauer and Stephen Chi-Tin Yang and Kristina C. Gregory and Miranda Hughes},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  year={2017},
  volume={15 4},
  pages={
          504-535
        }
}
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates. 

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 138 CITATIONS, ESTIMATED 45% COVERAGE

Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma

  • Journal of Cancer Research and Clinical Oncology
  • 2018
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer

  • Journal of clinical medicine
  • 2018
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 16 Highly Influenced Citations

  • Averaged 46 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 251 REFERENCES

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016